Anthra Pharmaceuticals offers Valstar bladder cancer treatment. The development-stage company acquires and develops late-stage drug candidates that treat bladder, ovarian, and prostate cancer, as well as complications from metastatic cancer. Anthra icensed Valstar -- which was approved by the Food and Drug Administration in 1998 -- to Medeva for sale in the US. In addition, Anthra has acquired the US development and marketing rights to Bonefos, a treatment for hypercalcemia and lytic bone disease, from Schering AG. Anthra Pharmaceuticals has facilities in Europe and the US.
